The majority of patients with recurrent prostate cancer have previously received androgen deprivation therapy and, despite an initial response, become castration-resistant after 2--3 years of treatment. The mechanism by which the tumour acquires castration resistance is still not completely understood, but recent evidence that even low levels of testosterone can activate androgen receptor (AR) and its signalling cascade has led to the search for novel therapeutic strategies that specifically target members of AR pathway ([@bib3]; [@bib15]).

Abiraterone is a potent and selective inhibitor of cytochrome P450 17 *α*-hydrolase (CYP17A1) enzyme that blocks androgen synthesis in the adrenal glands, testicles and tumour microenvironment ([@bib22]; [@bib2]; [@bib11]). A randomised phase III trial of abiraterone *vs* placebo in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel showed a significant increase in progression-free survival (PFS) and overall survival (OS) ([@bib7]; [@bib12]). Moreover, a randomised phase III trial of abiraterone *vs* placebo in CRPC patients in the pre-docetaxel space reported an advantage in PFS and OS from abiraterone treatment ([@bib23], [@bib24]). These findings led to a large-scale use of abiraterone in clinical practice, but it has now become essential to identify the mechanisms of drug resistance so that patients who are most likely to benefit can be selected for treatment.

CYP17A1 and AR would seem to be the two most important actors in the AR signalling axis in the acquisition of resistance to abiraterone treatment ([@bib13]; [@bib16]). The CYP17A1enzyme is the specific target of abiraterone and catalyses key reactions in sex-steroid biosynthesis by mediating 17*α*-hydrolase and 17,20-lyase activities. Its gene is located on chromosome 10q24.3 ([@bib30]). Intratumoral CYP17A1 overexpression has been detected in prostate cancer tissue biopsies from patients treated with abiraterone, suggesting that upregulation of the enzyme could have a key role in resistance to treatment ([@bib4]; [@bib16]). The *AR* gene is located on chromosome Xq12. It is known to be frequently amplified in prostate cancer tissue, especially in CRPC, and correlates with high protein expression, resulting in a putative escape mechanism from therapies targeting AR signalling ([@bib9]; [@bib13]). The role of these genes as potential circulating biomarkers has yet to be explored.

The prognostic potential of circulating tumour DNA (liquid biopsy) has also been evaluated in prostate cancer in an attempt to identify biomarkers that are capable of predicting outcome and of monitoring the effect of specific therapies ([@bib27]; [@bib10]). We hypothesised that genomic changes in *CYP17A1* and *AR* genes may influence the sensitivity of CRPC cells to abiraterone.

In the present study, we analysed copy number variations (CNVs) of *CYP17A1* and *AR* genes in serum cell-free DNA of CRPC patients treated with abiraterone and then correlated them with clinical outcome.

Materials and methods
=====================

Study design
------------

Patients with metastatic CRPC without neuroendocrine differentiation in progression after docetaxel and treated with abiraterone were included in this retrospective study. Inclusion criteria were as follows: baseline serum testosterone \<50 ng dl^−1^; Eastern Cooperative Oncology Group (ECOG) performance status ⩽2; adequate cardiac, hepatic, renal and bone marrow function; serum potassium level ⩾3.5 mmol l^−1^; and ongoing androgen deprivation therapy. Prior treatment with ketoconazole was not permitted. Patient serum was collected before the start of abiraterone treatment. Blood samples were drawn into 10-ml tubes without anticoagulant, which were maintained at room temperature, processed within 30 min, and stored at −80 °C. The study protocol was approved by IRST Ethical Committee and all patients signed informed consent.

Antitumour therapy consisted of 28-day cycles of daily abiraterone acetate 1000 mg with twice-daily prednisone 5 mg. Abiraterone was continued until there was evidence of progressive disease (PD) or unacceptable toxicity. Before starting therapy, patients underwent a baseline blood PSA assessment and a chest and abdominal CT scan. PSA response and toxicity were evaluated on a monthly basis. A CT scan was then performed every 3 months during treatment with abiraterone. Progressive disease was defined on the basis of Prostate Cancer Working Group 2 (PCWG2) criteria ([@bib25]). Adverse events were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.

Detecting copy number gain of *AR* and *CYP17A1* in blood from CRPC patients
----------------------------------------------------------------------------

CNV analyses of the two target genes were performed for all samples by duplex TaqMan quantitative real-time PCR (qPCR) assay (Applied Biosystems, Foster City, CA, USA). Androgen receptor and *CYP17A1* genes were each evaluated in two loci using different assays. *RNaseP*, located on 14q11, was selected as the internal standard reference gene. This region is not known to be aberrant in prostate cancer. Serum DNA was extracted using QIAamp DNA Mini Kit (Qiagen, Milan, Italy), according to the manufacturer\'s instructions. DNA quality and concentration were determined using spectrophotometry quantification (NanoDrop ND-1000, Celbio, Milan, Italy). For each sample, 20 ng of DNA was analysed in triplicate using TaqMan Genotyping Master Mix and the primers for target and reference sequences. Three serum DNAs from healthy males over 40 years were singly tested, and then pooled and used as a calibrator, sample with no CNVs of target gene ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). In the same run, each sample was evaluated for the two loci of the target gene (TaqMan Copy Number Assays ID: Hs04107225 (*AR* 1) and Hs04511283 (*AR* 2); Hs01583974 (*CYP17A1* 1) and Hs05126409 (*CYP17A1* 2)). Standard deviation results are reported in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

Copy number variation analysis was performed using relative quantitation method by CopyCaller Software (Applied Biosystems). Final results were calculated as the average between the copy number values of the two gene loci. For *CYP17A1*, values \>2.5 were considered as amplification and \<1.5 as deletion. For *AR*, the cutoffs were \>1.5 for amplification and \<0.5 for deletion. Cutoffs were selected considering the copy number calculated for the healthy sample replicate group ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}) and of LNCap cell line ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

We calculated the copy number corrected, using the formula:

where *CN*=copy number variation observed; *ploidy*=1 for *AR* and 2 for *CYP17A1*; *SC*=sample content: percentage of DNA from patient in respect to total serum DNA.

Validation data with digital PCR
--------------------------------

We validated samples for *AR* and *CYP17A1* CNV with QuantStudio3D digital PCR system (Life Technologies, Carlsbad, CA, USA). The total PCR volume was 15 *μ*l, containing serum DNA (15 ng), 0.9 *μ*l of TaqMan assay for the genes of interest, 0.9 *μ*l of the probe for the reference gene (*RNaseP*), and 9 *μ*l of QuantStudio 3D Master mix (Life Technologies). The PCR was analysed by QuantStudio 3D software (Life Technologies). Poisson distribution was used to estimate the average number of copies per reaction microlitres. Ratio between target copies and reference copies was calculated for each sample. The results were compared with the healthy DNA pool.

Statistical analysis
--------------------

Progression-free survival was defined as the time between the first day of treatment with abiraterone and the date of PD or death (whichever came first). Patients who had not progressed at database closure were censored at the final follow-up or discontinuation of treatment due to toxicity. Overall survival was defined as the time between the first day of abiraterone treatment and the date of death from any cause or the date of the last follow-up visit.

The association between CNVs and clinical outcome was evaluated by the Kaplan--Meier method and log-rank test. The percentage of early PD during treatment was calculated after 4 months by *AR* and *CYP17A1* CNVs and compared using the Chi-Square test. A Cox regression model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for PFS and OS. The multivariable Cox models included all factors that were significantly associated in the univariate models. The area under the receiver operating characteristic (ROC) curves and sensitivity and specificity indices were calculated to assess the diagnostic performance of CNVs in detecting progression and death. An area under the ROC curve close to one indicated high diagnostic accuracy. All *P*-values were two-sided and a *P*\<0.05 was considered as statistically significant. Statistical analyses were performed with SAS 9.3 software (SAS Institute, Cary, NC, USA).

Results
=======

*AR* and *CYP17A1* copy number gain in CRPC
-------------------------------------------

Fifty-three consecutive patients with metastatic CRPC who previously received docetaxel-based chemotherapy were treated with abiraterone between March 2011 and August 2012. Serum samples were collected at baseline and analysed for CNVs of *AR* and *CYP17A1* genes. The median DNA concentration extracted was 6.8 ng *μ*l^−1^ (range: 2.5--14.3 ng *μ*l^−1^). Androgen receptor was gained in 16 cases and *CYP17A1* in 15. Ten patients showed gain of both genes. No gene losses were detected. Data were validated by digital PCR (dPCR) experiments ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Approach sensitivity was tested using different ratio between DNA from patients, with *AR* and *CYP17A1* gain, and DNA from healthy volunteers mixed together: the approach proved capable of detecting CNVs even when very low amounts of patients DNA were used. In particular, when the gene copy number was high, only 0.375% of DNA from patients was needed to detect the gain, for example, sample 2 ([Figure 1A](#fig1){ref-type="fig"}). We also calculated the correct CNV in relation with the percentage of patient DNA ([Figure 1B](#fig1){ref-type="fig"}).

The clinical characteristics of patients in relation to differences in CNVs of *AR* and *CYP17A1* are reported in [Table 1](#tbl1){ref-type="table"}. Patients with an ECOG performance status of 0-1 *vs* 2 showed a statistically significant association with CNVs of *AR* and *CYP17A1* genes and the combination of them (*P*=0.0209; *P*=0.0150; *P*=0.0023, respectively). Median baseline PSA, ALP and LDH levels were significantly associated with CNVs in both genes ([Table 1](#tbl1){ref-type="table"}).

Correlation with PSA decline and early progressive disease
----------------------------------------------------------

A PSA decline of ⩾50% was reported in 26 (49%) of the 53 patients (5 out of 16 (31%) with *AR* gene gain and 21 out of 37 (57%) individuals with no gain) (*P*=0.0881). Furthermore, PSA decline was significantly correlated with CNV of *CYP17A1* present in 4 (27%) of the 15 patients with *CYP17A1* gain and in 22 (58%) of the 38 individuals with no gain (*P*=0.0405).

Early PD, defined according to the PCWGC2 as treatment interruption occurring within 4 months of the start of abiraterone, was observed in 18 (34%) of the 53 patients. It was significantly correlated with CNVs of both *AR* and *CYP17A1*, occurring in 10 (62.5%) of the 16 patients with *AR* gene gain and in 8 (22%) of the 37 individuals with no gain (*P*=0.0039), and in 11 (73%) of the 15 patients with *CYP17A1* gain and in 7 (18%) of the 38 individuals with no gain (*P*=0.0001).

Association with outcome
------------------------

At the time of analysis, 44 of the 53 patients had PD and 30 patients had died. The median PFS and OS for the overall population were 6.8 months (95% CI: 4.6--9.7) and 17.6 months (95% CI: 10.8--21.9), respectively ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). Overall, abiraterone was well tolerated, the majority of side effects reported as grade 1 or 2. Treatment-related complications requiring the interruption of abiraterone were heart failure (1 patient) and grade 3 hypertransaminase (1). The drug was also suspended for non treatment-related infective diarrhea (1 patient), pulmonary thromboembolism (1) and renal failure (1).

The median PFS of patients with *AR* gene gain was 2.8 months (95% CI: 2.2--5.6) *vs* 9.5 months (95% CI: 6.7--12.7) of those with no CNVs (*P*\<0.0001). Patients with *CYP17A1* gene gain had a median PFS of 2.8 months (95% CI: 0.9--4.3) *vs* 9.2 months (95% CI: 6.6--12.7) of those with two copies of the gene (*P*=0.0014). Considering the two gene CNVs together, we observed an increase in the difference between the median PFS values of patients with both genes gained compared to those with normal gene copy numbers: 2.5 months (95% CI: 0.3--2.9) *vs* 10.1 months (95% CI: 6.7--12.7), respectively. Individuals with only *AR* or *CYP17A1* gain showed a median PFS of 5.3 months (95% CI: 2.4--14.8) (*P*\<0.0001) ([Figure 2](#fig2){ref-type="fig"}).

The median OS of patients with *AR* gene gain was 5.0 months (95% CI: 2.7--12.3) compared with 21.9 months (95% CI: 14.4--NR) for individuals with one copy of the gene (*P*\<0.0001). Patients with *CYP17A1* gain showed a median OS of 4.3 months (95% CI: 1.8--18.6) *vs* 19.0 months of individuals with no gain (95% CI: 12.2--NR) (*P*=0.0085). The OS curve for the two genes combined showed 2.9 months (95% CI: 0.8--12.3) for the patients with two-gene gain and 21.9 months (95% CI: 14.4--NR) for individuals with normal copy number. A median OS of 10.8 months (95% CI: 3.2--NR) was observed for only one gene gain (*P*=0.0001) ([Figure 3](#fig3){ref-type="fig"}).

Both raw and adjusted hazard ratios for PFS and OS are summarised in [Table 2](#tbl2){ref-type="table"}. Multivariate analysis for PFS showed a significant association with *AR* and *CYP17A1* CNVs (*P*=0.0004 and 0.0450, respectively), and PSA decline ⩾50% (*P*\<0.0001). The same analysis for OS revealed a significant association with ECOG performance status (*P*=0.0021), PSA decline ⩾50% (*P*=0.0014), *AR* CNV (*P*=0.0026) and DNA concentration (*P*=0.0129). We also analysed the sensitivity and specificity of CNVs in PFS and OS ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

Discussion
==========

In the present study, we showed a significant correlation between serum CNVs of *AR* and *CYP17A1* genes and the clinical outcome of metastatic CRPC patients treated with abiraterone. Androgen receptor and *CYP17A1* CNVs were associated with poor ECOG performance status, higher levels of PSA, ALP and LDH at baseline ([Table 1](#tbl1){ref-type="table"}). The majority of patients with *AR* or *CYP17A1* gain showed early PD that occurred within 4 months of the start of abiraterone treatment, indicating that CNVs of *AR* and *CYP17A1* genes are predictive of early resistance to therapy. Moreover, patients with CNVs of *AR* and/or *CYP17A1* genes had poor PFS and OS ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Multivariate analysis for PFS revealed a significant association with CNVs of *AR* and *CYP17A1* and PSA decline ⩾50%, while the same analysis for OS showed a significant association with ECOG performance status, *AR* CNV, PSA decline ⩾50% and DNA concentration ([Table 2](#tbl2){ref-type="table"}). Thus, DNA concentration would seem to have a prognostic role in these patients. The lack of a significant association between *CYP17A1* CNV and OS may be attributable to the effect of treatments administered after abiraterone, in particular enzalutamide, which is an inhibitor of AR but not of CYP17A1, so a potential impact on OS should be considered for these patients. If confirmed, then our results on CNVs of the *CYP17A1* gene could influence the decision to personalise treatment in these patients. However, the most effective therapy sequence has yet to be defined for these patients ([@bib18]; [@bib21]; [@bib26]).

The main limitations of this study were the small sample size and the absence of an independent validation set. Our results should thus be considered preliminary and hypothesis-generating. It can be hypothesised that abiraterone-resistant patients with *CYP17A1* gain but a normal *AR* copy number may benefit from treatment with enzalutamide and from other therapies that do not target *CYP17A1* (with a favourable impact on the OS). It would be interesting to evaluate the role of *AR* and *CYP17A1* CNVs in well-designed prospective studies on larger series of patients.

Of note, we evaluated *AR* and *CYP17A1* genes in serum circulating-free DNA. This 'liquid biopsy\' provides valuable information on the characteristics of disease at the time of blood sample collection, thus eliminating the need for biopsies at difficult metastatic sites ([@bib6]; [@bib20]). We analysed CNVs of specific regions: intron 1 and exon 3 of *CYP17A1* and the *AR* ligand-binding domain. Literature data report different regulation mechanisms and genomic alterations for *CYP17A1* ([@bib28]; [@bib13]; [@bib14]; [@bib19]; [@bib20]). [@bib13] showed that, although around 50% of metastatic CRPC exhibited *CYP17A1* heterozygous deletions, tumours were capable of upregulating CYP17A1 through methylation of CpG sites in the gene body. Conversely, we observed that *CYP17A1* was gained in about 28% of treated patients and hypothesised that this gain was correlated with higher expression. There may, in fact, be different mechanisms that regulate the expression of this enzyme involved in androgen synthesis ([@bib13]). When CYP17A1 is overexpressed, only a part of CYP17A1 molecules are inhibited by abiraterone and the tumour microenvironment may nonetheless continue to stimulate testosterone synthesis ([@bib19]). At the same time, *AR* amplification, leading to increased protein expression, could lead to *AR* axis activation in the absence of testosterone stimulation. These two resistance mechanisms could help to explain why patients with *AR* or *CYP17A1* gene amplification appear to be resistant to abiraterone. The *AR* gain is not a novel concept in the pathogenesis of prostate cancer and is known to be present in about 30% of CRPC patients, correlating with higher protein expression ([@bib29]). A recent study similarly showed that *AR* copy number gain and *AR* ligand binding domain point mutations associate with resistance to treatment ([@bib5]). Recently, an association has been found between a splice-variant of AR (AR-V7) and resistance to both abiraterone and enzalutamide, detecting in circulating tumour cells of CRPC patients ([@bib1]). Androgen receptor gene CNV and alternative splicing could be associated as resistance mechanisms.

In this era of personalised medicine, the importance of identifying new predictive markers for targeted therapies is now widely accepted in CRPC ([@bib17]; [@bib8]). Copy number variations will have an important role and new techniques such as next-generation sequencing (NGS) could accurately allow their estimation together with sequencing of somatic point mutations ([@bib5]). Our results highlighted AR and CYP17A1 CNVs as non-invasive markers capable of identifying patients who are likely to benefit from treatment with abiraterone. Larger prospective studies are warranted to validate these circulating biomarkers as predictors of outcome to treatment with abiraterone and possibly other hormone therapies in patients with CRPC.
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![**Approach sensitivity.** (**A**) CNV analysis of *AR* and *CYP17A1* genes from a healthy male and CRPC patient serum DNA pool. Blue line: cutoff for *AR* (1.5); red line: cutoff for *CYP17A1* (2.5). We tested series of different ratios of DNA from patient (gain of *AR* and *CYP17A1* gene) and healthy males mixed together for each sample. Patient DNA percentages were 0.375, 0.75, 1.5, 3, 6, 12, 25, 50 and 100, in respect to total serum DNA. The same healthy DNA was used as a calibrator. (**B**) Copy number corrected for *AR* (sample 1) and *CYP17A1* (sample 3). Note: sample 2 and sample 4 were analysed only for the points described due to insufficient DNA.](bjc2015128f1){#fig1}

![PFS---Kaplan Meier curves for *AR* (**A**), *CYP17A1* (**B**) and combined *AR*+*CYP17A1* (**C**). A=gene amplification; N=no gene aberration; AA=two-gene amplification; AN=only one gene amplification; NN=no aberrations for either gene.](bjc2015128f2){#fig2}

![OS---Kaplan Meier curves for *AR* (**A**), *CYP17A1* (**B**) and combined *AR*+*CYP17A1* (**C**). A=gene amplification; N=no aberration gene; AA=both genes amplification; AN=only one gene amplification; NN=no aberrations for either gene.](bjc2015128f3){#fig3}

###### Patient characteristics

                                                                      ***AR***        ***CYP17A1***      **AR+CYP17A1 combined**                                                                                                             
  ---------------------------------------------- ---------------- ---------------- -------------------- ------------------------- ----------------- -------------------- -------- ---------------- -------------------- -------------------- --------
  Total                                              53 (100)         37 (100)           16 (100)                  --                 38 (100)            15 (100)          --        32 (100)           10 (100)             11 (100)          --
  Median age, years (range)                        74 (57--87)      74 (57--87)        74 (57--85)               0.6787              73 (57--87)        76 (57--86)       0.3139    74 (57--87)        77 (57--85)          72 (61--86)       0.3465
  **Gleason score**                                                                                                                                                                                                                          
  6--7                                               23 (43)          18 (49)             5 (31)                 0.3137                16 (42)             7 (47)         0.6112      14 (44)             3 (30)               6 (55)         0.6232
  8--9                                               29 (55)          19 (51)            10 (63)                                       22 (58)             7 (47)                     18 (56)             6 (60)               5 (45)            
  Unknown                                             1 (2)              --               1 (6)                                          --                1 (7)                         --               1 (10)                 --              
  **ECOG PS**                                                                                                                                                                                                                                
  0--1                                               46 (87)          35 (95)            11 (69)                 0.0209                36 (95)            10 (67)         0.0150      30 (94)             5 (50)              11 (100)        0.0023
  2                                                   7 (13)           2 (5)              5 (31)                                        2 (5)              5 (33)                      2 (6)              5 (50)                 --              
  **Bone metastases**                                                                                                                                                                                                                        
  No                                                  9 (17)           8 (22)             1 (6)                  0.2484                7 (18)              2 (13)         1.0000       6 (19)               --                 3 (27)         0.2656
  Yes                                                44 (83)          29 (78)            15 (94)                                       31 (82)            13 (87)                     26 (81)            10 (100)              8 (73)            
  **Visceral metastases**                                                                                                                                                                                                                    
  No                                                 41 (77)          29 (78)            12 (75)                  1.000                30 (79)            11 (73)         0.7220      25 (78)             7 (70)               9 (82)         0.8087
  Yes                                                12 (23)           8 (22)             4 (25)                                       8 (21)              4 (27)                      7 (22)             3 (30)               2 (18)            
  **No. of previous chemotherapeutic lines**                                                                                                                                                                                                 
  1                                                  25 (47)          19 (51)            6 (37.5)                0.3537                20 (53)             5 (33)         0.2049      18 (56)             4 (40)               3 (27)         0.2217
  2 or more                                          28 (53)          18 (49)           10 (62.5)                                      18 (47)            10 (67)                     14 (44)             6 (60)               8 (73)            
  Median baseline PSA level, ng ml^−1^ (range)    33.1 (1--1501)   19.7 (1--1501)   152.9 (13.2--1435)           0.0064            21.9 (1--1501)    292.4 (13.8--1435)   0.0006   15.9 (1--1501)   278.3 (13.8--1435)   129.7 (13.2--1083)   0.0007
  Median baseline ALP level, mU ml^−1^ (range)    117 (35--1144)   83 (35--1144)      454 (68--1071)             0.0017            93.5 (36--1144)    383.5 (35--1071)    0.0219   86 (36--1144)      590 (84--1071)       181 (35--1018)     0.0032
  Median baseline LDH level, mU ml^−1^ (range)    201 (48--999)    192 (48--542)     268.5 (121--999)            0.0290             192 (48--961)      250 (166--999)     0.0173   189 (48--542)      287 (203--999)      224.5 (121--961)    0.0154

Abbreviations; ALP=alkaline phosphatase; A=amplified; *AR*=androgen receptor; *CYP17A1*=cytochrome P450 17 *α*-hydrolase; ECOG=Eastern Cooperative Oncology Group; LDH=lactate dehydrogenase; N=normal; PS=performance status; PSA=prostate-specific antigen.

###### Univariate and multivariate analyses for progression-free survival and for overall survival

                                                        **Progression-free survival**   **Overall survival**                                                                                       
  ------------------------------------ --------------- ------------------------------- ---------------------- -------------------- ---------- -------------------- ---------- -------------------- --------
  Age, years                           \<75 *vs* ⩾75          1.11 (0.61--2.02)                0.7259                                          0.94 (0.46--1.94)     0.8755                            
  Visceral metastases                  Yes *vs* no            0.05 (0.47--1.97)                0.9038                                          1.04 (0.44--2.48)     0.9293                            
  No. of previous lines of treatment   ⩾2 *vs* 1              1.50 (0.82--2.75)                0.1858                                          2.01 (0.92--4.41)     0.0804                            
  ECOG PS                              2 *vs* 0--1            1.91 (0.84--4.35)                0.1236                                          3.29 (1.32--8.22)     0.0107    5.37 (1.84--15.69)   0.0021
  PSA decline⩾50%                      No *vs* yes            4.90 (2.49--9.62)               \<0.0001         6.24 (2.91--13.37)   \<0.0001   4.34 (1.95--9.67)     0.0003    4.23 (1.74--10.24)   0.0014
  *AR* CNV                             A *vs* N               3.73 (1.95--7.13)               \<0.0001         4.06 (1.86--8.86)     0.0004    4.68 (2.17--10.10)   \<0.0001   3.59 (1.38--9.31)    0.0026
  *CYP17A1* CNV                        A *vs* N               2.79 (1.45--5.35)                0.0021          2.20 (1.02--4.77)     0.0450    2.61 (1.24--5.48)     0.0111    0.92 (0.37--2.29)    0.8576
  DNA concentration                    ng *μ*l^−1^            1.14 (1.02--1.28)                0.0263          1.06 (0.93--1.21)     0.3911    1.24 (1.09--1.42)     0.0015    1.22 (1.04--1.43)    0.0129

Abbreviations: A=amplified; *AR*=androgen receptor; CI=confidence interval; CNV=copy number variation; *CYP17A1*=cytochrome P450 A1; ECOG=Eastern Cooperative Oncology Group; HR=hazard ratio; PS=performance status; PSA=prostate-specific antigen; N=normal.
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